KEY TAKEAWAYS
- This study aimed to determine the biological functions of NCAPD2 in LUAD and investigate its potential as a therapeutic target.
- NCAPD2 shows promise as a prognostic biomarker for LUAD and a potential target for novel therapies.
Lung adenocarcinoma (LUAD) is a common type of lung cancer with a complex pathogenesis. Identifying reliable biomarkers for early diagnosis and treatment is crucial for improving patient outcomes. NCAPD2, a protein often overexpressed in various tumors, has been implicated in tumor development and progression. However, its specific role in LUAD remains unclear.
Peiling Wu and the team aimed to explore the biological functions of NCAPD2 in LUAD and elucidate its underlying mechanisms.
Researchers used bioinformatics approaches to analyze the expression levels of NCAPD2 in LUAD. They compared NCAPD2 expression in tumor and normal samples from The Cancer Genome Atlas (TCGA) LUAD dataset, examining its correlation with clinicopathological characteristics, survival prognosis, and immune infiltration.
They performed in vitro experiments to assess the impact of silencing NCAPD2 on LUAD cell proliferation, migration, invasion, epithelial-mesenchymal transition (EMT), and cell cycle progression.
Analysis of the TCGA-LUAD dataset revealed significantly higher NCAPD2 expression in tumor samples compared to normal samples (P< 0.001). Higher NCAPD2 expression correlated significantly with advanced TNM stage, worse overall survival, and specific demographic and clinical characteristics like gender and smoking status.
Gene expression analysis identified a strong association between NCAPD2 and pathways involved in cell division. Additionally, NCAPD2 expression showed links to the infiltration of various immune cells, including memory B cells, naïve CD4+ T cells, activated memory CD4+ T cells, and M1 macrophages. In vitro experiments demonstrated that silencing NCAPD2 inhibited LUAD cell proliferation, migration, invasion, EMT, and cell cycle progression.
The findings of this study suggested that NCAPD2 plays a significant role in LUAD development and progression. Its elevated expression correlates with advanced disease stages and poorer prognosis. Moreover, NCAPD2 appears to influence LUAD cell proliferation, migration, and invasion, suggesting its potential as a therapeutic target.
No funding information was available.
Source: https://pubmed.ncbi.nlm.nih.gov/39220139/
Wu P, Zhao L, Zhang H, et al. (2024). “NCAPD2 serves as a potential prognostic biomarker for lung adenocarcinoma and promotes cell proliferation, migration, invasion and cell cycle in vitro.” Oncol Res. 2024;32(9):1439-1452. Published 2024 Aug 23. doi:10.32604/or.2024.047490
